Company intelligence / Profile preview

Cytoki Pharma

Søborg, Capital Region, Denmarkcytokipharma.com ↗

Ownership: Private
Employees: ~7
Development stage: Phase 2

Overview

Cytoki Pharma is a clinical-stage biotech company developing a new class of medicines based on IL‑22 biology. Their lead candidate, CK‑0045, is in Phase 2 trials and aims to address metabolic diseases such as obesity and type 2 diabetes by driving healthy weight loss and broader metabolic effects. The company’s approach leverages the unique properties of IL‑22 to target epithelial tissues involved in these conditions. Early data suggest differentiated efficacy compared to existing therapies like GLP‑1 agonists, with potential for fewer gastrointestinal side effects[1][4].

Therapeutic areas: GastroenterologyEndocrinologyDermatology
Modalities: Protein therapeuticsLong-acting IL‑22 analogues[1][4]
Industry: Biotech

Drug pipeline

1 asset

CK-0045

Beyond the preview

Go deeper on Cytoki Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytoki Pharma.

Explore the full profile